Medicare Drug Price Negotiation: Few Drugs, Big Impact?

Although Medicare’s new drug price negotiation authority under the Inflation Reduction Act applies to only a small number of high‑spending drugs, it could affect a much larger share of spending through price “spillover” to competing products. Even limited negotiations may therefore yield substantial savings for patients and taxpayers, though design flaws in Part D and Part B payment rules could blunt these effects without further reform.